Propofol versus midazolam for sedation during radiofrequency ablation in patients with hepatocellular carcinoma
Abstract Background and Aim Standardization of the sedation protocol during radiofrequency ablation (RFA) in patients with hepatocellular carcinoma (HCC) is needed. This randomized, single‐blind, investigator‐initiated trial compared clinical outcomes during and after RFA using propofol and midazola...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-02-01
|
| Series: | JGH Open |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jgh3.12483 |
| _version_ | 1818725606961971200 |
|---|---|
| author | Naoya Kanogawa Sadahisa Ogasawara Yoshihiko Ooka Masanori Inoue Toru Wakamatsu Masayuki Yokoyama Susumu Maruta Hidemi Unozawa Terunao Iwanaga Takafumi Sakuma Naoto Fujita Keisuke Koroki Hiroaki Kanzaki Takahiro Maeda Kazufumi Kobayashi Soichiro Kiyono Masato Nakamura Takayuki Kondo Tomoko Saito Tenyu Motoyama Eiichiro Suzuki Shingo Nakamoto Akinobu Tawada Tetsuhiro Chiba Makoto Arai Tatsuo Kanda Hitoshi Maruyama Jun Kato Ryo Takemura Natsuko Nozaki‐Taguchi Isono Shiroh Osamu Yokosuka Naoya Kato |
| author_facet | Naoya Kanogawa Sadahisa Ogasawara Yoshihiko Ooka Masanori Inoue Toru Wakamatsu Masayuki Yokoyama Susumu Maruta Hidemi Unozawa Terunao Iwanaga Takafumi Sakuma Naoto Fujita Keisuke Koroki Hiroaki Kanzaki Takahiro Maeda Kazufumi Kobayashi Soichiro Kiyono Masato Nakamura Takayuki Kondo Tomoko Saito Tenyu Motoyama Eiichiro Suzuki Shingo Nakamoto Akinobu Tawada Tetsuhiro Chiba Makoto Arai Tatsuo Kanda Hitoshi Maruyama Jun Kato Ryo Takemura Natsuko Nozaki‐Taguchi Isono Shiroh Osamu Yokosuka Naoya Kato |
| author_sort | Naoya Kanogawa |
| collection | DOAJ |
| description | Abstract Background and Aim Standardization of the sedation protocol during radiofrequency ablation (RFA) in patients with hepatocellular carcinoma (HCC) is needed. This randomized, single‐blind, investigator‐initiated trial compared clinical outcomes during and after RFA using propofol and midazolam, respectively, in patients with HCC. Methods Few‐ and small‐nodule HCC patients (≤3 nodules and ≤3 cm) were randomly assigned to either propofol or midazolam. Patient satisfaction was assessed using a 100‐mm visual analog scale (VAS) (1 mm = not at all satisfied, 100 mm = completely satisfied). Sedation recovery rates 1, 2, 3, and 4 h after RFA were evaluated based on Modified Observer's Assessment of Alertness/Sedation (MOAA/S) scores; full recovery was defined as a MOAA/S score of 5. Results Between July 2013 and September 2017, 143 patients with HCC were enrolled, and 135 patients were randomly assigned to the treatment group. Compared with midazolam, propofol exhibited similar median procedural satisfaction (propofol: 73.1 mm, midazolam: 76.9 mm, P = 0.574). Recovery rates 1 and 2 h after RFA were higher in the propofol group than in the midazolam group. Meanwhile, recovery rates observed 3 and 4 h after RFA were similar in the two groups. The safety profiles during and after RFA were almost identical in the two groups. Conclusion Patient satisfaction was almost identical in patients receiving propofol and midazolam sedation during RFA. Propofol sedation resulted in reduced recovery time compared with midazolam sedation in patients with HCC. The safety profiles of both propofol and midazolam sedation during and after RFA were acceptable. |
| first_indexed | 2024-12-17T21:44:59Z |
| format | Article |
| id | doaj.art-7f27397a7ce3413e8772f8b1cbb15834 |
| institution | Directory Open Access Journal |
| issn | 2397-9070 |
| language | English |
| last_indexed | 2024-12-17T21:44:59Z |
| publishDate | 2021-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | JGH Open |
| spelling | doaj.art-7f27397a7ce3413e8772f8b1cbb158342022-12-21T21:31:29ZengWileyJGH Open2397-90702021-02-015227327910.1002/jgh3.12483Propofol versus midazolam for sedation during radiofrequency ablation in patients with hepatocellular carcinomaNaoya Kanogawa0Sadahisa Ogasawara1Yoshihiko Ooka2Masanori Inoue3Toru Wakamatsu4Masayuki Yokoyama5Susumu Maruta6Hidemi Unozawa7Terunao Iwanaga8Takafumi Sakuma9Naoto Fujita10Keisuke Koroki11Hiroaki Kanzaki12Takahiro Maeda13Kazufumi Kobayashi14Soichiro Kiyono15Masato Nakamura16Takayuki Kondo17Tomoko Saito18Tenyu Motoyama19Eiichiro Suzuki20Shingo Nakamoto21Akinobu Tawada22Tetsuhiro Chiba23Makoto Arai24Tatsuo Kanda25Hitoshi Maruyama26Jun Kato27Ryo Takemura28Natsuko Nozaki‐Taguchi29Isono Shiroh30Osamu Yokosuka31Naoya Kato32Department of Gastroenterology, Graduate School of Medicine Chiba University Chiba JapanDepartment of Gastroenterology, Graduate School of Medicine Chiba University Chiba JapanDepartment of Gastroenterology, Graduate School of Medicine Chiba University Chiba JapanDepartment of Gastroenterology, Graduate School of Medicine Chiba University Chiba JapanDepartment of Gastroenterology, Graduate School of Medicine Chiba University Chiba JapanDepartment of Gastroenterology, Graduate School of Medicine Chiba University Chiba JapanDepartment of Gastroenterology, Graduate School of Medicine Chiba University Chiba JapanDepartment of Gastroenterology, Graduate School of Medicine Chiba University Chiba JapanDepartment of Gastroenterology, Graduate School of Medicine Chiba University Chiba JapanDepartment of Gastroenterology, Graduate School of Medicine Chiba University Chiba JapanDepartment of Gastroenterology, Graduate School of Medicine Chiba University Chiba JapanDepartment of Gastroenterology, Graduate School of Medicine Chiba University Chiba JapanDepartment of Gastroenterology, Graduate School of Medicine Chiba University Chiba JapanDepartment of Gastroenterology, Graduate School of Medicine Chiba University Chiba JapanDepartment of Gastroenterology, Graduate School of Medicine Chiba University Chiba JapanDepartment of Gastroenterology, Graduate School of Medicine Chiba University Chiba JapanDepartment of Gastroenterology, Graduate School of Medicine Chiba University Chiba JapanDepartment of Gastroenterology, Graduate School of Medicine Chiba University Chiba JapanDepartment of Gastroenterology, Graduate School of Medicine Chiba University Chiba JapanDepartment of Gastroenterology, Graduate School of Medicine Chiba University Chiba JapanDepartment of Gastroenterology, Graduate School of Medicine Chiba University Chiba JapanDepartment of Gastroenterology, Graduate School of Medicine Chiba University Chiba JapanDepartment of Gastroenterology, Graduate School of Medicine Chiba University Chiba JapanDepartment of Gastroenterology, Graduate School of Medicine Chiba University Chiba JapanDepartment of Gastroenterology, Graduate School of Medicine Chiba University Chiba JapanDepartment of Gastroenterology, Graduate School of Medicine Chiba University Chiba JapanDepartment of Gastroenterology, Graduate School of Medicine Chiba University Chiba JapanDepartment of Gastroenterology, Graduate School of Medicine Chiba University Chiba JapanClinical and Translational Research Center Keio University Hospital Tokyo JapanDepartmetn of Anesthesiology, Graduate School of Medicine Chiba University Chiba JapanDepartmetn of Anesthesiology, Graduate School of Medicine Chiba University Chiba JapanDepartment of Gastroenterology, Graduate School of Medicine Chiba University Chiba JapanDepartment of Gastroenterology, Graduate School of Medicine Chiba University Chiba JapanAbstract Background and Aim Standardization of the sedation protocol during radiofrequency ablation (RFA) in patients with hepatocellular carcinoma (HCC) is needed. This randomized, single‐blind, investigator‐initiated trial compared clinical outcomes during and after RFA using propofol and midazolam, respectively, in patients with HCC. Methods Few‐ and small‐nodule HCC patients (≤3 nodules and ≤3 cm) were randomly assigned to either propofol or midazolam. Patient satisfaction was assessed using a 100‐mm visual analog scale (VAS) (1 mm = not at all satisfied, 100 mm = completely satisfied). Sedation recovery rates 1, 2, 3, and 4 h after RFA were evaluated based on Modified Observer's Assessment of Alertness/Sedation (MOAA/S) scores; full recovery was defined as a MOAA/S score of 5. Results Between July 2013 and September 2017, 143 patients with HCC were enrolled, and 135 patients were randomly assigned to the treatment group. Compared with midazolam, propofol exhibited similar median procedural satisfaction (propofol: 73.1 mm, midazolam: 76.9 mm, P = 0.574). Recovery rates 1 and 2 h after RFA were higher in the propofol group than in the midazolam group. Meanwhile, recovery rates observed 3 and 4 h after RFA were similar in the two groups. The safety profiles during and after RFA were almost identical in the two groups. Conclusion Patient satisfaction was almost identical in patients receiving propofol and midazolam sedation during RFA. Propofol sedation resulted in reduced recovery time compared with midazolam sedation in patients with HCC. The safety profiles of both propofol and midazolam sedation during and after RFA were acceptable.https://doi.org/10.1002/jgh3.12483hepatocellular carcinomamidazolampropofolradiofrequency ablationsedation |
| spellingShingle | Naoya Kanogawa Sadahisa Ogasawara Yoshihiko Ooka Masanori Inoue Toru Wakamatsu Masayuki Yokoyama Susumu Maruta Hidemi Unozawa Terunao Iwanaga Takafumi Sakuma Naoto Fujita Keisuke Koroki Hiroaki Kanzaki Takahiro Maeda Kazufumi Kobayashi Soichiro Kiyono Masato Nakamura Takayuki Kondo Tomoko Saito Tenyu Motoyama Eiichiro Suzuki Shingo Nakamoto Akinobu Tawada Tetsuhiro Chiba Makoto Arai Tatsuo Kanda Hitoshi Maruyama Jun Kato Ryo Takemura Natsuko Nozaki‐Taguchi Isono Shiroh Osamu Yokosuka Naoya Kato Propofol versus midazolam for sedation during radiofrequency ablation in patients with hepatocellular carcinoma JGH Open hepatocellular carcinoma midazolam propofol radiofrequency ablation sedation |
| title | Propofol versus midazolam for sedation during radiofrequency ablation in patients with hepatocellular carcinoma |
| title_full | Propofol versus midazolam for sedation during radiofrequency ablation in patients with hepatocellular carcinoma |
| title_fullStr | Propofol versus midazolam for sedation during radiofrequency ablation in patients with hepatocellular carcinoma |
| title_full_unstemmed | Propofol versus midazolam for sedation during radiofrequency ablation in patients with hepatocellular carcinoma |
| title_short | Propofol versus midazolam for sedation during radiofrequency ablation in patients with hepatocellular carcinoma |
| title_sort | propofol versus midazolam for sedation during radiofrequency ablation in patients with hepatocellular carcinoma |
| topic | hepatocellular carcinoma midazolam propofol radiofrequency ablation sedation |
| url | https://doi.org/10.1002/jgh3.12483 |
| work_keys_str_mv | AT naoyakanogawa propofolversusmidazolamforsedationduringradiofrequencyablationinpatientswithhepatocellularcarcinoma AT sadahisaogasawara propofolversusmidazolamforsedationduringradiofrequencyablationinpatientswithhepatocellularcarcinoma AT yoshihikoooka propofolversusmidazolamforsedationduringradiofrequencyablationinpatientswithhepatocellularcarcinoma AT masanoriinoue propofolversusmidazolamforsedationduringradiofrequencyablationinpatientswithhepatocellularcarcinoma AT toruwakamatsu propofolversusmidazolamforsedationduringradiofrequencyablationinpatientswithhepatocellularcarcinoma AT masayukiyokoyama propofolversusmidazolamforsedationduringradiofrequencyablationinpatientswithhepatocellularcarcinoma AT susumumaruta propofolversusmidazolamforsedationduringradiofrequencyablationinpatientswithhepatocellularcarcinoma AT hidemiunozawa propofolversusmidazolamforsedationduringradiofrequencyablationinpatientswithhepatocellularcarcinoma AT terunaoiwanaga propofolversusmidazolamforsedationduringradiofrequencyablationinpatientswithhepatocellularcarcinoma AT takafumisakuma propofolversusmidazolamforsedationduringradiofrequencyablationinpatientswithhepatocellularcarcinoma AT naotofujita propofolversusmidazolamforsedationduringradiofrequencyablationinpatientswithhepatocellularcarcinoma AT keisukekoroki propofolversusmidazolamforsedationduringradiofrequencyablationinpatientswithhepatocellularcarcinoma AT hiroakikanzaki propofolversusmidazolamforsedationduringradiofrequencyablationinpatientswithhepatocellularcarcinoma AT takahiromaeda propofolversusmidazolamforsedationduringradiofrequencyablationinpatientswithhepatocellularcarcinoma AT kazufumikobayashi propofolversusmidazolamforsedationduringradiofrequencyablationinpatientswithhepatocellularcarcinoma AT soichirokiyono propofolversusmidazolamforsedationduringradiofrequencyablationinpatientswithhepatocellularcarcinoma AT masatonakamura propofolversusmidazolamforsedationduringradiofrequencyablationinpatientswithhepatocellularcarcinoma AT takayukikondo propofolversusmidazolamforsedationduringradiofrequencyablationinpatientswithhepatocellularcarcinoma AT tomokosaito propofolversusmidazolamforsedationduringradiofrequencyablationinpatientswithhepatocellularcarcinoma AT tenyumotoyama propofolversusmidazolamforsedationduringradiofrequencyablationinpatientswithhepatocellularcarcinoma AT eiichirosuzuki propofolversusmidazolamforsedationduringradiofrequencyablationinpatientswithhepatocellularcarcinoma AT shingonakamoto propofolversusmidazolamforsedationduringradiofrequencyablationinpatientswithhepatocellularcarcinoma AT akinobutawada propofolversusmidazolamforsedationduringradiofrequencyablationinpatientswithhepatocellularcarcinoma AT tetsuhirochiba propofolversusmidazolamforsedationduringradiofrequencyablationinpatientswithhepatocellularcarcinoma AT makotoarai propofolversusmidazolamforsedationduringradiofrequencyablationinpatientswithhepatocellularcarcinoma AT tatsuokanda propofolversusmidazolamforsedationduringradiofrequencyablationinpatientswithhepatocellularcarcinoma AT hitoshimaruyama propofolversusmidazolamforsedationduringradiofrequencyablationinpatientswithhepatocellularcarcinoma AT junkato propofolversusmidazolamforsedationduringradiofrequencyablationinpatientswithhepatocellularcarcinoma AT ryotakemura propofolversusmidazolamforsedationduringradiofrequencyablationinpatientswithhepatocellularcarcinoma AT natsukonozakitaguchi propofolversusmidazolamforsedationduringradiofrequencyablationinpatientswithhepatocellularcarcinoma AT isonoshiroh propofolversusmidazolamforsedationduringradiofrequencyablationinpatientswithhepatocellularcarcinoma AT osamuyokosuka propofolversusmidazolamforsedationduringradiofrequencyablationinpatientswithhepatocellularcarcinoma AT naoyakato propofolversusmidazolamforsedationduringradiofrequencyablationinpatientswithhepatocellularcarcinoma |